 |
04.02.2013
Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call
|
14.2 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its first quarter 2013 investor update conference call and webcast at
8:30 a.m. Eastern Time on Tuesday, April 23, 2013. Individuals
interested in participating in the call should dial (877) 643...
|
|
03.04.2013
Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors
|
245.5 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment
of Edward Owens to its board of directors. Mr. Owens is a recently
retired partner, portfolio manager and global industry analyst with
Wellington Management Company, LLP.
...
|
|
02.25.2013
Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference
|
13.9 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the Cowen and Company 33rd Annual Health Care Conference
on Monday, March 4, 2013 at 4:10 p.m. Eastern Time at The Boston
Marriott Copley Place.
A live webcast of ...
|
|
02.11.2013
Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D
|
194.4 KB |
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the promotion
of Mark
Currie, Ph.D. to senior vice president, chief scientific officer
(CSO), and president of research and development (R&D).
Mark Currie, Ph.D., senior vice president...
|
|
01.15.2013
Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update
|
166.8 KB |
| |
Initiated Promotional Efforts for LINZESS™ (linaclotide) with Forest
in December 2012; LINZESS Available to Patients in Pharmacies Across
U.S.; Forest Reported $19.2 Million in Net Sales of LINZESS in Fourth
Quarter 2012
Almirall Received Approval from European Commission for Con...
|
|
|
